INTERLEUKIN-35 IN ANKYLOSING SPONDYLITIS: ASSOCIATION WITH DISEASE ACTIVITY AND RADIOGRAPHIC PROGRESSION

Presenter
  • Anna Abou-Raya (Egypt)
Lecture Time
08:20 - 08:26

Abstract

Background and Aims

Radiographic axial spondyloarthritis/ankylosing spondylitis (AS) is a chronic inflammatory arthritis characterized by sacroiliitis, enthesitis and a marked propensity for sacroiliac joint and spinal fusion. Interleukin 35 (IL-35) is the newest identified member of the interleukin-12 cytokine family, a unique group of heterodimeric cytokines including IL-12, IL-23, IL-27, and IL-35, which share structural similarities but mediate diverse immunological functions.Accordingly, the objective of of the present study was to examine the impact of IL-35 in AS patients and assess the association between serum IL-35 levels, disease activity and radiographic progression including bone erosions.

Methods

Forty AS patients diagnosed according to the ASAS/EULAR criteria, and 20 controls were recruited. Serum IL-35 levels were measured by ELISA. Disease activity and health outcome measures assessed included: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),Bath Ankylosing Spondylitis Functional Index(BASFI), Bath Ankylosing Spondylitis Metrology Index(BASMI), Ankylosing Spondylitis Disease Activity Score-C reactive protein(ASDASCRP), Maastricht Ankylosing Spondylitis Enthesitis Score and Patient Global Assessment score. Radiographic assessment of the spine and sacroiliac joints was done using the Modified Stoke Ankylosing Spondylitis Spinal Score.

Results

The mean serum IL-35 level in AS patients was significantly less compared to controls, 14.68±2.72 pg/ml versus 30.62±6.04 pg/ml; p< 0.001. A significant correlation was found between serum IL-35 levels and BASDAI(r=-0.363, p=0.021), BASMI r=-0.605, p< 0.001), and ASDASCRP(r= -0.597, p<0.001) respectively. Higher IL-35 levels were associated with less bony erosions.

Conclusions

IL- 35 has a protective role in AS; it is associated with less disease activity and better health outcomes. IL-35 is thus a potential therapeutic target for AS.

Hide